Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb to Report Results for Third Quarter 2021 on October 27, 2021

Bristol Myers Squibb to Report Results for Third Quarter 2021 on October 27, 2021

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #C2C4C--More than 230 Bristol Myers Squibb Employees Pedal Across the U.S. to Advance Cancer Research in Seventh Annual Coast 2 Coast 4 Cancer Ride

More than 230 Bristol Myers Squibb Employees Pedal Across the U.S. to Advance Cancer Research in Seventh Annual Coast 2 Coast 4 Cancer Ride

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Research at ESMO 2021 Demonstrates Clinical Benefits of Immunotherapies in Multiple Hard-to-Treat Advanced or Metastatic Cancers.....

Bristol Myers Squibb Research at ESMO 2021 Demonstrates Clinical Benefits of Immunotherapies in Multiple Hard-to-Treat Advanced or Metastatic Cancers and Reinforces the Benefit of Opdivo in Earlier-Stage Cancers

Amgen

Enterprise Products Partners

Merck

Pembina Pipeline

Reinsurance Group of America

Unum

In this article, we're looking at the companies I consider the most investable for September of 2021. I look for investment-graded dividend-paying stocks with a conservative RoR of no less than 15% over a 3-4-year period.

Undervalued Dividend Stocks For September With 10-20% Upside

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb to Take Part in Morgan Stanley 19th Annual Global Healthcare Conference

Bristol Myers Squibb to Take Part in Morgan Stanley 19th Annual Global Healthcare Conference

Evotec SE (OTC: EVTCY) says that Bristol Myers Squibb Co (NYSE: BMY) has exercised its option to enter into an exclusive global license for EVT8683. It is the first program from the companies' broader neurodegeneration collaboration.

Bristol Myers Exercises Option In-License Evotec's Neurodegenerative Candidate

AbbVie

Johnson & Johnson

Now is not the time to sell healthcare. Biopharma offers some of the highest quality bargains in the entire market right now.

4 Blue Chip Bargains In The Biopharma Space

The Wall Street Analyst consensus on BMY is overwhelmingly bullish.

Bristol Myers Squibb: Why Wall Street Is Wrong About The Stock

The stock price of ​Bristol Myers Squibb has seen a 4% drop over the last five trading sessions led by a recent sell-off in large-cap pharmaceutical stocks over the past week or so, with Johnson & Johnson, Pfizer, and Merck also falling over 3% each. Looking at a little longer time period.

Will Bristol Myers Squibb Stock Rebound After A 4% Fall Last Week?

Bank of America

Salesforce

Kirkland Lake Gold

Novavax

It doesn't take a boatload of money to begin or further your trek to financial independence.

5 No-Brainer Stocks to Invest $400 in Right Now

Bristol Myers (BMY) reported earnings 30 days ago. What's next for the stock?

Bristol Myers (BMY) Down 1.7% Since Last Earnings Report: Can It Rebound?

The FDA accepts Bristol Myers' (BMY) sBLA for Orencia under a priority review to prevent moderate to severe acute graft versus host disease. A verdict is pending on Dec 23, 2021.

Bristol Myers' (BMY) sBLA for Orencia Gets FDA Priority Review

Cameco

Equity Commonwealth

MasTec

Invitae

Muhlenkamp & Co. Inc., the investment firm founded by Ronald Muhlenkamp (Trades, Portfolio), released its portfolio for the second quarter earlier this month.

Ron Muhlenkamp's Firm Goes 1 for 1 in 2nd Quarter

Bristol Myers' (BMY) Opdivo gets label expansion in the United States for adjuvant treatment of patients with high-risk urothelial carcinoma.

Bristol Myers' (BMY) Opdivo Approved for Another Indication

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ABA2--US FDA Accepts for Priority Review BMS's Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD)

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD)

Bristol Myers (BMY) wins EC approval for its CAR T cell immunotherapy, Abecma, for the treatment of multiple myeloma.

Bristol Myers (BMY) CAR T Cell Therapy Abecma Approved by EC

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--U.S. Food and Drug Administration Approves Opdivo® (nivolumab) for the Adjuvant Treatment of Patients with High-Risk Urothelial Carcinoma

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) for the Adjuvant Treatment of Patients with High-Risk Urothelial Carcinoma

The European Commission (EC) has granted conditional marketing approval for Bristol Myers Squibb & Co's (NYSE: BMY) Abecma (idecabtagene vicleucel, ide-cel) for relapsed and refractory multiple myeloma. Abecma is a first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy.

Europe Approves Bristol Myers' BCMA-Targeted Multiple Myeloma Immunotherapy

Some estimates show that BMY has as much as 100% upside at fair prices. After digging into this stock - I'm not so sure about that story.

Bristol Myers Squibb: Not As Much Upside As You Think

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ABECMA--BMS Receives European Commission Approval for Abecma, the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma

Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma

Amazon

BorgWarner

Organon & Co

The S&P 500 is potentially on track for the greatest year in market history and is 30% historically overvalued.

4 Incredible Blue-Chip Bargains You Won't Want To Miss

General Motors

U.S. Bancorp

Berkshire Hathaway's stakes in these top-tier companies were reduced during the second quarter.

3 Stocks Warren Buffett Is Selling That You Should Be Buying Hand Over Fist

Biogen

Kroger

Buffett stocks are a hot topic among investors as they look to go long on some fresh plays. Kroger and Aon are among Berkshire's favorites.

7 Buffett Stocks to Buy (and Sell) if You Want to Be Like Berkshire

Yesterday, Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway ( BRK.A , Financial)( BRK.B , Financial) published its 13F report for the period ending June 30.

Warren Buffett Sells Biotech Holdings After a Year

Cisco Systems

Fortis

You can expect your dividend income to rise over the years with these impressive companies.

News for Bristol-Myers Stock (BMY)